Biomarkers as predictors in rheumatoid arthritis.
Rheumatoid arthritis is a heterogeneous disease which complicates treatment of the patients. To identify patients with similar pathogenesis would be a great step towards victory in the field of rheumatology. Different studies have shown different molecules as potential key biomarkers for the pathology. Our project is conducted in collaboration with Crescendo Bioscience company (CA, USA), who developed a Multi-Biomarker Disease Activity (MBDA) score based on serum concentration of 12 individual biomarkers. We are analysing the MBDA scores at baseline, 3 and 12 months of early RA patients from the SWEFOT randomized clinical trial. Current findings are the potential usefulness of the MBDA score at BL for predicting radiographic non-progression of joint damage over the following one year. This work has been presented orally and as poster at EULAR and ACR annual meetings in 2013 and a submitted manuscript is in a process of review. Further analyses showed that the MBDA score may be useful to complement the CRP as an inclusion criterion for clinical trials in RA, revealing patients with high disease activity hidden by low CRP. In addition, the change of the MBDA score during 3 months initial MTX therapy might be useful for decision concerning treatment of non-responders either with non-biological DMARDs or anti-TNF drugs. The last two studies have been submitted for presentation at EULAR 2014 congress in Paris.
The future plans are to analyse the individual biomarkers that comprise the MBDA score and their possible combination for identification of patients who would respond clinically and/or radiographically to different treatments. This information can be translated into clinical practice and help in decision making for the optimal therapy for individual patients.
Karen Hambardzumyan, graduate student
08-517 730 65